Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

Listed in the December 27, 2023 extract; not in the current extract (Aug 26, 2026): Ceftriaxone Sodium for Injection, BP (02250276), Ceftriaxone for Injection USP (02292866), Ceftriaxone Sodium for Injection, BP (02250292), Ceftriaxone for Injection USP (02292882), Ceftriaxone for Injection USP (02292904). Source: odb-formulary-ed43-extract-2023-12-27.xml; compared with odb-formulary-ed43-extract-2026-08-26.xml.

CEFTRIAXONE DISODIUM

10 general benefit · 6 not a benefit

Other products in the same Health Canada class (J01D, J01DD) — coverage varies; not interchangeable

  • Cefixime (Suprax): general benefit
  • Cefadroxil (Duricef): general benefit, Not a benefit
  • Cefprozil (Ran-Cefprozil): general benefit, Not a benefit
  • Cefuroxime axetil (Ceftin): general benefit, Not a benefit
  • Cephalexin (Ceporex): general benefit, Not a benefit
  • Cefazolin (Cefazolin for Injection): not a benefit

1 more in the class list below

Ceftriaxone Sodium For Injection BP · DIN 02325594 · 0.25g/Vial · powder for injection, vial

General benefitMarketed · checked 2026-09-19
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Ceftriaxone Sodium For Injection BP · DIN 02325594 Manufacturer: Sterimax Inc.; listing date 2016-03-30 Health Canada: Marketed since 2011-04-23 · brand CEFTRIAXONE SODIUM FOR INJECTION BP · ATC J01DD04 CEFTRIAXONE · form Powder for solution · route Intramuscular, Intravenous · ingredients CEFTRIAXONE (CEFTRIAXONE SODIUM) 250 MG/VIAL · company Sterimax inc · schedule Prescription
Check this DIN again · Health Canada product record

Ceftriaxone Sodium For Injection BP: Formulary list price $5.6430/unit (unit not stated in source; not the patient's cost)

Ministry pays: $5.6430 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81096 · Verify on the e-Formulary ↗ (DIN 02325594)

Source record
DIN 02325594: Ceftriaxone Sodium For Injection BP Raw flags: sec3=Y Item: 081228043; group id 41; item number 0087; lccId None; manufacturer id STE Source form: Inj Pd-Vial Pk; strength: 0.25g/Vial Recorded listing: General benefit Source prices (unrounded): $5.6430; ministry $5.6430 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02325594 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81096
Interchangeable products
Ceftriaxone Sodium for Injection BP · DIN 02292262 · $5.6430 Rocephin · DIN 00657387 · not recorded
Shortage status: To be discontinued; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02325594
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Ceftriaxone Sodium for Injection BP · DIN 02292262 · 0.25g/Vial · powder for injection, vial

General benefitMarketed · checked 2026-09-18
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Ceftriaxone Sodium for Injection BP · DIN 02292262 Manufacturer: Sandoz Canada Inc.; listing date 2026-08-31 Health Canada: Marketed since 2018-03-15 · brand CEFTRIAXONE SODIUM FOR INJECTION BP · ATC J01DD04 CEFTRIAXONE · form Powder for solution · route Intravenous, Intramuscular · ingredients CEFTRIAXONE (CEFTRIAXONE SODIUM) 250 MG/VIAL · company Sandoz canada incorporated · schedule Prescription
Check this DIN again · Health Canada product record

Ceftriaxone Sodium for Injection BP: Formulary list price $5.6430/unit (unit not stated in source; not the patient's cost)

Ministry pays: $5.6430 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77762 · Verify on the e-Formulary ↗ (DIN 02292262)

Source record
DIN 02292262: Ceftriaxone Sodium for Injection BP Raw flags: sec3=Y Item: 081228043; group id 41; item number 0087; lccId None; manufacturer id SDZ Source form: Inj Pd-Vial Pk; strength: 0.25g/Vial Recorded listing: General benefit Source prices (unrounded): $5.6430; ministry $5.6430 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02292262 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77762
Interchangeable products
Ceftriaxone Sodium For Injection BP · DIN 02325594 · $5.6430 Rocephin · DIN 00657387 · not recorded
Shortage status: resolved shortage (ended 2024-01-08); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02292262
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Ceftriaxone · DIN 02292270 · 1g/Vial · powder for injection, vial

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Ceftriaxone · DIN 02292270 Manufacturer: Sandoz Canada Inc.; listing date 2007-05-04 Health Canada: Marketed since 2018-03-15 · brand CEFTRIAXONE SODIUM FOR INJECTION BP · ATC J01DD04 CEFTRIAXONE · form Powder for solution · route Intramuscular, Intravenous · ingredients CEFTRIAXONE (CEFTRIAXONE SODIUM) 1 G/VIAL · company Sandoz canada incorporated · schedule Prescription
Check this DIN again · Health Canada product record

Ceftriaxone: Formulary list price $12.4950/unit (unit not stated in source; not the patient's cost)

Ministry pays: $12.4950 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77763 · Verify on the e-Formulary ↗ (DIN 02292270)

Source record
DIN 02292270: Ceftriaxone Raw flags: sec3=Y Item: 081228045; group id 41; item number 0088; lccId None; manufacturer id SDZ Source form: Inj Pd-Vial Pk; strength: 1g/Vial Recorded listing: General benefit Source prices (unrounded): $12.4950; ministry $12.4950 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02292270 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77763
Interchangeable products
Ceftriaxone Sodium For Injection BP · DIN 02325616 · $12.4950 Ceftriaxone Sodium for Injection · DIN 02287633 · $12.4950 Ceftriaxone for Injection · DIN 02289695 · $12.4950 Ceftriaxone for Injection USP · DIN 02292874 · $12.4950 Rocephin · DIN 00657417 · not recorded
Shortage status: resolved shortage (ended 2019-11-01); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02292270
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Ceftriaxone Sodium For Injection BP · DIN 02325616 · 1g/Vial · powder for injection, vial

General benefitMarketed · checked 2026-09-18
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Ceftriaxone Sodium For Injection BP · DIN 02325616 Manufacturer: Sterimax Inc.; listing date 2016-03-30 Health Canada: Marketed since 2011-03-21 · brand CEFTRIAXONE SODIUM FOR INJECTION BP · ATC J01DD04 CEFTRIAXONE · form Powder for solution · route Intramuscular, Intravenous · ingredients CEFTRIAXONE (CEFTRIAXONE SODIUM) 1 G/VIAL · company Sterimax inc · schedule Prescription
Check this DIN again · Health Canada product record

Ceftriaxone Sodium For Injection BP: Formulary list price $12.4950/unit (unit not stated in source; not the patient's cost)

Ministry pays: $12.4950 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81098 · Verify on the e-Formulary ↗ (DIN 02325616)

Source record
DIN 02325616: Ceftriaxone Sodium For Injection BP Raw flags: sec3=Y Item: 081228045; group id 41; item number 0088; lccId None; manufacturer id STE Source form: Inj Pd-Vial Pk; strength: 1g/Vial Recorded listing: General benefit Source prices (unrounded): $12.4950; ministry $12.4950 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02325616 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81098
Interchangeable products
Ceftriaxone · DIN 02292270 · $12.4950 Ceftriaxone Sodium for Injection · DIN 02287633 · $12.4950 Ceftriaxone for Injection · DIN 02289695 · $12.4950 Ceftriaxone for Injection USP · DIN 02292874 · $12.4950 Rocephin · DIN 00657417 · not recorded
Shortage status: resolved shortage (ended 2024-12-19); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02325616
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Ceftriaxone for Injection · DIN 02289695 · 1g/Vial · powder for injection, vial

General benefitMarketed · checked 2026-09-19
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Ceftriaxone for Injection · DIN 02289695 Manufacturer: Fresenius Kabi Canada Ltd.; listing date 2025-03-31 Health Canada: Marketed since 2024-08-15 · brand CEFTRIAXONE FOR INJECTION · ATC J01DD04 CEFTRIAXONE · form Powder for solution · route Intravenous, Intramuscular · ingredients CEFTRIAXONE (CEFTRIAXONE SODIUM) 1 G/VIAL · company Fresenius kabi canada ltd · schedule Prescription
Check this DIN again · Health Canada product record

Ceftriaxone for Injection: Formulary list price $12.4950/unit (unit not stated in source; not the patient's cost)

Ministry pays: $12.4950 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77503 · Verify on the e-Formulary ↗ (DIN 02289695)

Source record
DIN 02289695: Ceftriaxone for Injection Raw flags: sec3=Y Item: 081228045; group id 41; item number 0088; lccId None; manufacturer id FKC Source form: Inj Pd-Vial Pk; strength: 1g/Vial Recorded listing: General benefit Source prices (unrounded): $12.4950; ministry $12.4950 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02289695 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77503
Interchangeable products
Ceftriaxone · DIN 02292270 · $12.4950 Ceftriaxone Sodium For Injection BP · DIN 02325616 · $12.4950 Ceftriaxone Sodium for Injection · DIN 02287633 · $12.4950 Ceftriaxone for Injection USP · DIN 02292874 · $12.4950 Rocephin · DIN 00657417 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02289695
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Ceftriaxone · DIN 02292289 · 2g/Vial · powder for injection, vial

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Ceftriaxone · DIN 02292289 Manufacturer: Sandoz Canada Inc.; listing date 2007-05-04 Health Canada: Marketed since 2018-03-15 · brand CEFTRIAXONE SODIUM FOR INJECTION BP · ATC J01DD04 CEFTRIAXONE · form Powder for solution · route Intravenous, Intramuscular · ingredients CEFTRIAXONE (CEFTRIAXONE SODIUM) 2 G/VIAL · company Sandoz canada incorporated · schedule Prescription
Check this DIN again · Health Canada product record

Ceftriaxone: Formulary list price $24.1395/unit (unit not stated in source; not the patient's cost)

Ministry pays: $24.1395 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77764 · Verify on the e-Formulary ↗ (DIN 02292289)

Source record
DIN 02292289: Ceftriaxone Raw flags: sec3=Y Item: 081228046; group id 41; item number 0089; lccId None; manufacturer id SDZ Source form: Inj Pd-Vial Pk; strength: 2g/Vial Recorded listing: General benefit Source prices (unrounded): $24.1395; ministry $24.1395 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02292289 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77764
Interchangeable products
Ceftriaxone Sodium For Injection BP · DIN 02325624 · $24.1395 Ceftriaxone for Injection · DIN 02289709 · $24.1395 Rocephin · DIN 00657409 · not recorded
Shortage status: shortage reported ended 2026-09-08 (report last updated 2026-09-08); confirm supply with the pharmacy; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02292289
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Ceftriaxone Sodium For Injection BP · DIN 02325624 · 2g/Vial · powder for injection, vial

General benefitMarketed · checked 2026-09-18
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Ceftriaxone Sodium For Injection BP · DIN 02325624 Manufacturer: Sterimax Inc.; listing date 2016-03-30 Health Canada: Marketed since 2011-01-31 · brand CEFTRIAXONE SODIUM FOR INJECTION BP · ATC J01DD04 CEFTRIAXONE · form Powder for solution · route Intramuscular, Intravenous · ingredients CEFTRIAXONE (CEFTRIAXONE SODIUM) 2 G/VIAL · company Sterimax inc · schedule Prescription
Check this DIN again · Health Canada product record

Ceftriaxone Sodium For Injection BP: Formulary list price $24.1395/unit (unit not stated in source; not the patient's cost)

Ministry pays: $24.1395 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81099 · Verify on the e-Formulary ↗ (DIN 02325624)

Source record
DIN 02325624: Ceftriaxone Sodium For Injection BP Raw flags: sec3=Y Item: 081228046; group id 41; item number 0089; lccId None; manufacturer id STE Source form: Inj Pd-Vial Pk; strength: 2g/Vial Recorded listing: General benefit Source prices (unrounded): $24.1395; ministry $24.1395 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02325624 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81099
Interchangeable products
Ceftriaxone · DIN 02292289 · $24.1395 Ceftriaxone for Injection · DIN 02289709 · $24.1395 Rocephin · DIN 00657409 · not recorded
Shortage status: resolved shortage (ended 2024-12-19); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02325624
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Ceftriaxone for Injection · DIN 02289709 · 2g/Vial · powder for injection, vial

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Ceftriaxone for Injection · DIN 02289709 Manufacturer: Fresenius Kabi Canada Ltd.; listing date 2025-03-31 Health Canada: Marketed since 2024-08-15 · brand CEFTRIAXONE FOR INJECTION · ATC J01DD04 CEFTRIAXONE · form Powder for solution · route Intramuscular, Intravenous · ingredients CEFTRIAXONE (CEFTRIAXONE SODIUM) 2 G/VIAL · company Fresenius kabi canada ltd · schedule Prescription
Check this DIN again · Health Canada product record

Ceftriaxone for Injection: Formulary list price $24.1395/unit (unit not stated in source; not the patient's cost)

Ministry pays: $24.1395 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77504 · Verify on the e-Formulary ↗ (DIN 02289709)

Source record
DIN 02289709: Ceftriaxone for Injection Raw flags: sec3=Y Item: 081228046; group id 41; item number 0089; lccId None; manufacturer id FKC Source form: Inj Pd-Vial Pk; strength: 2g/Vial Recorded listing: General benefit Source prices (unrounded): $24.1395; ministry $24.1395 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02289709 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77504
Interchangeable products
Ceftriaxone · DIN 02292289 · $24.1395 Ceftriaxone Sodium For Injection BP · DIN 02325624 · $24.1395 Rocephin · DIN 00657409 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02289709
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Ceftriaxone Sodium For Injection BP · DIN 02292297 · 10g/Vial · powder for injection, vial

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Ceftriaxone Sodium For Injection BP · DIN 02292297 Manufacturer: Sandoz Canada Inc.; listing date 2022-04-29 Health Canada: Marketed since 2018-03-15 · brand CEFTRIAXONE SODIUM FOR INJECTION BP · ATC J01DD04 CEFTRIAXONE · form Powder for solution · route Intravenous · ingredients CEFTRIAXONE (CEFTRIAXONE SODIUM) 10 G/VIAL · company Sandoz canada incorporated · schedule Prescription
Check this DIN again · Health Canada product record

Ceftriaxone Sodium For Injection BP: Formulary list price $214.2000/unit (unit not stated in source; not the patient's cost)

Ministry pays: $214.2000 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77765 · Verify on the e-Formulary ↗ (DIN 02292297)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02292297). DIN 02292297: Ceftriaxone Sodium For Injection BP Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 081228121; group id 41; item number 0090; lccId None; manufacturer id SDZ Source form: Inj Pd-Vial Pk; strength: 10g/Vial Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $214.2000; ministry $214.2000 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02292297 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77765
Interchangeable products
Ceftriaxone Sodium For Injection BP · DIN 02325632 · $214.2000 Rocephin · DIN 00851957 · not recorded
Shortage status: resolved shortage (ended 2026-04-20); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02292297
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Ceftriaxone Sodium For Injection BP · DIN 02325632 · 10g/Vial · powder for injection, vial

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-18
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Ceftriaxone Sodium For Injection BP · DIN 02325632 Manufacturer: Sterimax Inc.; listing date 2016-03-30 Health Canada: Marketed since 2011-03-21 · brand CEFTRIAXONE SODIUM FOR INJECTION BP · ATC J01DD04 CEFTRIAXONE · form Powder for solution · route Intravenous · ingredients CEFTRIAXONE (CEFTRIAXONE SODIUM) 10 G/VIAL · company Sterimax inc · schedule Prescription
Check this DIN again · Health Canada product record

Ceftriaxone Sodium For Injection BP: Formulary list price $214.2000/unit (unit not stated in source; not the patient's cost)

Ministry pays: $214.2000 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81100 · Verify on the e-Formulary ↗ (DIN 02325632)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02325632). DIN 02325632: Ceftriaxone Sodium For Injection BP Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 081228121; group id 41; item number 0090; lccId None; manufacturer id STE Source form: Inj Pd-Vial Pk; strength: 10g/Vial Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $214.2000; ministry $214.2000 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02325632 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81100
Interchangeable products
Ceftriaxone Sodium For Injection BP · DIN 02292297 · $214.2000 Rocephin · DIN 00851957 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02325632
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Ceftriaxone Sodium for Injection · DIN 02287633 · 1g/Vial · powder for injection, vial

General benefit; Health Canada lists this DIN as Cancelled post market since 2025-07-30 — choose a marketed DIN from the same-category list.Discontinued 2025-07-30 · checked 2026-09-19
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2025-07-30 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2025-07-30 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Ceftriaxone Sodium for Injection · DIN 02287633 Manufacturer: Teva Canada Limited; listing date 2008-03-25 Health Canada: Cancelled post market since 2025-07-30 · brand CEFTRIAXONE SODIUM FOR INJECTION · ATC J01DD04 CEFTRIAXONE · form Powder for solution · route Intramuscular, Intravenous · ingredients CEFTRIAXONE (CEFTRIAXONE SODIUM) 1 G/VIAL · company Teva canada limited · schedule Prescription
Check this DIN again · Health Canada product record

Ceftriaxone Sodium for Injection: Formulary list price $12.4950/unit (unit not stated in source; not the patient's cost)

Ministry pays: $12.4950 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77304 · Verify on the e-Formulary ↗ (DIN 02287633)

Source record
DIN 02287633: Ceftriaxone Sodium for Injection Raw flags: sec3=Y Item: 081228045; group id 41; item number 0088; lccId None; manufacturer id TEV Source form: Inj Pd-Vial Pk; strength: 1g/Vial Recorded listing: General benefit Source prices (unrounded): $12.4950; ministry $12.4950 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02287633 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77304
Interchangeable products
Ceftriaxone · DIN 02292270 · $12.4950 Ceftriaxone Sodium For Injection BP · DIN 02325616 · $12.4950 Ceftriaxone for Injection · DIN 02289695 · $12.4950 Ceftriaxone for Injection USP · DIN 02292874 · $12.4950 Rocephin · DIN 00657417 · not recorded
Shortage status: discontinued (2021-02-05, reported by TEVA CANADA LIMITED); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02287633
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2025-07-30 — choose a marketed DIN from the same-category list.

Ceftriaxone for Injection USP · DIN 02292874 · 1g/Vial · powder for injection, vial

General benefit; Health Canada lists this DIN as Cancelled post market since 2019-06-28 — choose a marketed DIN from the same-category list.Discontinued 2019-06-28 · checked 2026-09-19
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2019-06-28 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2019-06-28 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Ceftriaxone for Injection USP · DIN 02292874 Manufacturer: Orchid Healthcare; listing date 2008-01-15 Health Canada: Cancelled post market since 2019-06-28 · brand CEFTRIAXONE FOR INJECTION USP · ATC J01DD04 CEFTRIAXONE · form Powder for solution · route Intramuscular, Intravenous · ingredients CEFTRIAXONE (CEFTRIAXONE SODIUM) 1 G/VIAL · company Pfizer canada ulc · schedule Prescription
Check this DIN again · Health Canada product record

Ceftriaxone for Injection USP: Formulary list price $12.4950/unit (unit not stated in source; not the patient's cost)

Ministry pays: $12.4950 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77822 · Verify on the e-Formulary ↗ (DIN 02292874)

Source record
DIN 02292874: Ceftriaxone for Injection USP Raw flags: sec3=Y Item: 081228045; group id 41; item number 0088; lccId None; manufacturer id ORC Source form: Inj Pd-Vial Pk; strength: 1g/Vial Recorded listing: General benefit Source prices (unrounded): $12.4950; ministry $12.4950 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02292874 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77822
Interchangeable products
Ceftriaxone · DIN 02292270 · $12.4950 Ceftriaxone Sodium For Injection BP · DIN 02325616 · $12.4950 Ceftriaxone Sodium for Injection · DIN 02287633 · $12.4950 Ceftriaxone for Injection · DIN 02289695 · $12.4950 Rocephin · DIN 00657417 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02292874
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2019-06-28 — choose a marketed DIN from the same-category list.

Rocephin · DIN 00657387 · 0.25g/Vial · powder for injection, vial

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2012-06-20 — choose a marketed DIN from the same-category list.Discontinued 2012-06-20 · checked 2026-09-19
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2012-06-20 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2012-06-20 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Rocephin · DIN 00657387 Manufacturer: Hoffmann-La Roche Limited; listing date 1996-10-01 Health Canada: Cancelled post market since 2012-06-20 · brand ROCEPHIN PWS INJ 0.25GM/VIAL · ATC J01DD04 CEFTRIAXONE · form Powder for solution · route Intravenous, Intramuscular · ingredients CEFTRIAXONE (CEFTRIAXONE SODIUM) 250 MG/VIAL · company Hoffmann-la roche limited · schedule Prescription
Check this DIN again · Health Canada product record

Rocephin: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=8037 · Verify on the e-Formulary ↗ (DIN 00657387)

Source record
DIN 00657387: Rocephin Raw flags: notABenefit=Y, sec3=Y Item: 081228043; group id 41; item number 0087; lccId None; manufacturer id HLR Source form: Inj Pd-Vial Pk; strength: 0.25g/Vial Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00657387 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=8037
Interchangeable products
Ceftriaxone Sodium For Injection BP · DIN 02325594 · $5.6430 Ceftriaxone Sodium for Injection BP · DIN 02292262 · $5.6430
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00657387
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2012-06-20 — choose a marketed DIN from the same-category list.

Rocephin · DIN 00657417 · 1g/Vial · powder for injection, vial

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2011-10-17 — choose a marketed DIN from the same-category list.Discontinued 2011-10-17 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2011-10-17 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2011-10-17 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Rocephin · DIN 00657417 Manufacturer: Hoffmann-La Roche Limited; listing date 1996-10-01 Health Canada: Cancelled post market since 2011-10-17 · brand ROCEPHIN PWS 1GM/VIAL · ATC J01DD04 CEFTRIAXONE · form Powder for solution · route Intramuscular, Intravenous · ingredients CEFTRIAXONE (CEFTRIAXONE SODIUM) 1 G/VIAL · company Hoffmann-la roche limited · schedule Prescription
Check this DIN again · Health Canada product record

Rocephin: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=8074 · Verify on the e-Formulary ↗ (DIN 00657417)

Source record
DIN 00657417: Rocephin Raw flags: notABenefit=Y, sec3=Y Item: 081228045; group id 41; item number 0088; lccId None; manufacturer id HLR Source form: Inj Pd-Vial Pk; strength: 1g/Vial Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00657417 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=8074
Interchangeable products
Ceftriaxone · DIN 02292270 · $12.4950 Ceftriaxone Sodium For Injection BP · DIN 02325616 · $12.4950 Ceftriaxone Sodium for Injection · DIN 02287633 · $12.4950 Ceftriaxone for Injection · DIN 02289695 · $12.4950 Ceftriaxone for Injection USP · DIN 02292874 · $12.4950
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00657417
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2011-10-17 — choose a marketed DIN from the same-category list.

Rocephin · DIN 00657409 · 2g/Vial · powder for injection, vial

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2009-07-29 — choose a marketed DIN from the same-category list.Discontinued 2009-07-29 · checked 2026-09-19
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2009-07-29 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2009-07-29 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Rocephin · DIN 00657409 Manufacturer: Hoffmann-La Roche Limited; listing date 1996-10-01 Health Canada: Cancelled post market since 2009-07-29 · brand ROCEPHIN PWS 2GM/VIAL · ATC J01DD04 CEFTRIAXONE · form Powder for solution · route Intramuscular, Intravenous · ingredients CEFTRIAXONE (CEFTRIAXONE SODIUM) 2 G/VIAL · company Hoffmann-la roche limited · schedule Prescription
Check this DIN again · Health Canada product record

Rocephin: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=8038 · Verify on the e-Formulary ↗ (DIN 00657409)

Source record
DIN 00657409: Rocephin Raw flags: notABenefit=Y, sec3=Y Item: 081228046; group id 41; item number 0089; lccId None; manufacturer id HLR Source form: Inj Pd-Vial Pk; strength: 2g/Vial Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00657409 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=8038
Interchangeable products
Ceftriaxone · DIN 02292289 · $24.1395 Ceftriaxone Sodium For Injection BP · DIN 02325624 · $24.1395 Ceftriaxone for Injection · DIN 02289709 · $24.1395
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00657409
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2009-07-29 — choose a marketed DIN from the same-category list.

Rocephin · DIN 00851957 · 10g/Vial · powder for injection, vial

Off-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2009-07-29 — choose a marketed DIN from the same-category list.Discontinued 2009-07-29 · checked 2026-09-18
StatusOff-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2009-07-29 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2009-07-29 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Rocephin · DIN 00851957 Manufacturer: Hoffmann-La Roche Limited; listing date 2008-08-28 Health Canada: Cancelled post market since 2009-07-29 · brand ROCEPHIN INJ 10GM/VIAL · ATC J01DD04 CEFTRIAXONE · form Powder for solution · route Intravenous · ingredients CEFTRIAXONE (CEFTRIAXONE SODIUM) 10 G/VIAL · company Hoffmann-la roche limited · schedule Prescription
Check this DIN again · Health Canada product record

Rocephin: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=10475 · Verify on the e-Formulary ↗ (DIN 00851957)

Source record
DIN 00851957: Rocephin Raw flags: sec3=Y, sec3b=Y Item: 081228121; group id 41; item number 0090; lccId None; manufacturer id HLR Source form: Inj Pd-Vial Pk; strength: 10g/Vial Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00851957 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=10475
Interchangeable products
Ceftriaxone Sodium For Injection BP · DIN 02292297 · $214.2000 Ceftriaxone Sodium For Injection BP · DIN 02325632 · $214.2000
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00851957
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2009-07-29 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (08:12:28 Other Antibiotics) and how they are covered

Matched class: 08:12:28 Other Antibiotics

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: CEFIXIME, CLINDAMYCIN PALMITATE Some products covered without a code (check the product listing): CEFADROXIL, CEFPROZIL, CEFUROXIME AXETIL, CEPHALEXIN MONOHYDRATE, CLINDAMYCIN HCL, CLINDAMYCIN PHOSPHATE, TOBRAMYCIN, TOBRAMYCIN SULFATE 08:12:28 Other Antibiotics

CEFIXIME

· 4 products · General benefit · strengths: 20mg/mL, 400mg · Oral Susp, Tab

CEFADROXIL

· 4 products · Listed, not a benefit (1), General benefit (3) · strengths: 500mg · Cap

CEFPROZIL

· 17 products · General benefit (11), Listed, not a benefit (6) · strengths: 125mg/5mL, 250mg/5mL, 250mg, 500mg · Oral Susp-100mL Pk, Oral Susp-75mL Pk, Tab

CEFUROXIME AXETIL

· 9 products · General benefit (7), Listed, not a benefit (2) · strengths: 125mg/5mL, 250mg, 500mg · Susp, Tab

CEPHALEXIN MONOHYDRATE

· 29 products · Listed, not a benefit (6), General benefit (23) · strengths: 250mg, 500mg, 25mg/mL, 50mg/mL · Cap, Pd for Oral Susp, Tab

CEFAZOLIN SODIUM

· 15 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 500mg/Vial, 1g/Vial, 10g/Vial · Inj Pd-Vial Pk, Inj Pd-Vial Pk (Preservative-Free)

CEFOXITIN SODIUM

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 1g/Vial, 2g/Vial · Inj Pd-Vial Pk

CLINDAMYCIN HCL

· 20 products · Listed, not a benefit (2), General benefit (18) · strengths: 150mg, 300mg · Cap

CLINDAMYCIN PALMITATE

· 1 products · General benefit · strengths: 15mg/mL · Pd for Oral Susp

CLINDAMYCIN PHOSPHATE

· 2 products · General benefit (1), Listed, not a benefit (1) · strengths: 300mg/2mL · Inj Sol-2mL Pk

TOBRAMYCIN

· 3 products · Limited Use, codes 472 (1), General benefit (2) · strengths: 28mg, 300mg/5mL · Inh Pd-Cap, Inh Sol-5mL Pk

TOBRAMYCIN SULFATE

· 4 products · Listed, not a benefit (1), General benefit (3) · strengths: 80mg/2mL · Inj Sol-2mL Pk Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 08:12:28 and 4 more
Full class listing Related classes: 08:12:04 Antifungals, 08:12:07 Carbapenems, 08:12:12 Erythromycins, 08:12:16 Penicillins, 08:12:24 Tetracyclines, 08:14:08 Azoles Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: bone and joint infections, intra-abdominal infections, lower respiratory tract infections, skin and skin structure infections, urinary tract infections
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. No displayed matched alternative is a general benefit. CEFOXITIN SODIUM · Off-Formulary Interchangeable, not an ODB benefit 1 - Intra-abdominal infections such as peritonitis and intra-abdominal abscess PM: https://pdf.hres.ca/dpd_pm/00073366.PDF; date November 16, 2023; DIN 02128187; fetched 2026-09-10 Product monograph 4 - Urinary tract infections (including those caused by Serratia marcescens and Serratia spp.) PM: https://pdf.hres.ca/dpd_pm/00073366.PDF; date November 16, 2023; DIN 02128187; fetched 2026-09-10 Product monograph 5 - Lower respiratory tract infections PM: https://pdf.hres.ca/dpd_pm/00073366.PDF; date November 16, 2023; DIN 02128187; fetched 2026-09-10 Product monograph 6 - Bone and joint infections caused by Staphylococcus aureus PM: https://pdf.hres.ca/dpd_pm/00073366.PDF; date November 16, 2023; DIN 02128187; fetched 2026-09-10 Product monograph CLINDAMYCIN PHOSPHATE · General benefit (1), Listed, not a benefit (1) • Skin and skin structure infections including cellulitis, abscesses, and wound infections when caused by Streptococcus pyogenes, Staphylococcus aureus and anaerobes. PM: https://pdf.hres.ca/dpd_pm/00085906.PDF; date AUG 27, 2026; DIN 02230540; fetched 2026-09-10 Product monograph • Intra-abdominal infections including peritonitis and abdominal abscess when caused by susceptible anaerobes. Clindamycin should be given in conjunction with an antibiotic of appropriate gram negative aerobic spectrum. PM: https://pdf.hres.ca/dpd_pm/00085906.PDF; date AUG 27, 2026; DIN 02230540; fetched 2026-09-10 Product monograph • Bone and joint infections including osteomyelitis and septic arthritis when caused by sensitive strains of Staphylococcus aureus and anaerobes. PM: https://pdf.hres.ca/dpd_pm/00085906.PDF; date AUG 27, 2026; DIN 02230540; fetched 2026-09-10 Product monograph AMOXICILLIN & CLAVULANIC ACID · General benefit (22), Listed, not a benefit (3) • Lower Respiratory Tract Infections when caused by β-lactamase producing strains of H. influenzae, K. pneumoniae, S. aureus or Moraxella (Branhamella) catarrhalis. PM: https://pdf.hres.ca/dpd_pm/00084428.PDF; date 2026-04-24; DIN 01916874; fetched 2026-09-10 Product monograph CEFADROXIL · Listed, not a benefit (1), General benefit (3) • Skin and skin structure infections caused by Staphylococcus aureus and/or Group A ß– hemolytic streptococci. PM: https://pdf.hres.ca/dpd_pm/00056563.PDF; date May 20, 2020; DIN 02235134; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
1 INDICATIONS Ceftriaxone for Injection is indicated for the treatment of the following infections when caused by susceptible strains of the designated micro-organisms: • Lower Respiratory tract infections caused by E. coli, H. influenzae, K. pneumoniae and species, Staph. aureus, Strep. pneumoniae and species (excluding enterococci). • Urinary tract infections (complicated and uncomplicated) caused by E. coli, Klebsiella species, P. mirabilis and P. vulgaris. • Bacterial Septicemia caused by E. coli, H. influenzae, K. pneumoniae, Staph. aureus and Strep. pneumoniae, (excluding enterococci). • Skin and Skin Structure Infections caused by K. pneumoniae and species, P. mirabilis, Staph. aureus, Staph. epidermidis and Streptococcus species (excluding enterococci). • Bone and Joint Infections caused by Staph. aureus, Strep. pneumoniae and Streptococcus species (excluding enterococci). • Intra-Abdominal Infections caused by E.coli and K. pneumoniae. • Meningitis caused by H. influenzae, N. meningitidis, and Strep. pneumoniae. Ceftriaxone sodium should not be used for the treatment of meningitis caused by L. monocytogen… https://pdf.hres.ca/dpd_pm/00071552.PDF PM date: MAY 15, 2023 Source product: CEFTRIAXONE FOR INJECTION; DIN 02289695; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Ceftriaxone Sodium For Injection BP · DIN 02325594 Shortage status: To be discontinued; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02325594

Check this DIN again

Ceftriaxone · DIN 02292289 Shortage status: shortage reported ended 2026-09-08 (report last updated 2026-09-08); confirm supply with the pharmacy; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02292289

Check this DIN again

Ceftriaxone Sodium for Injection · DIN 02287633 Shortage status: discontinued (2021-02-05, reported by TEVA CANADA LIMITED); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02287633

Check this DIN again

Other review policies

For Ceftriaxone Sodium For Injection BP, Rocephin: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026